Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical and Molecular Spectrum of Liposarcoma
Alex Thomas John Lee, Khin Thway, Paul H. Huang, et al.
Journal of Clinical Oncology (2017) Vol. 36, Iss. 2, pp. 151-159
Open Access | Times Cited: 284

Showing 1-25 of 284 citing articles:

Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group
Carol J. Swallow, D. Strauß, Sylvie Bonvalot, et al.
Annals of Surgical Oncology (2021) Vol. 28, Iss. 12, pp. 7873-7888
Open Access | Times Cited: 172
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 135
Chlorin e6: A Promising Photosensitizer in Photo-Based Cancer Nanomedicine
Arshadul Hak, Mohammad Sadik Ali, Sri Amruthaa Sankaranarayanan, et al.
ACS Applied Bio Materials (2023) Vol. 6, Iss. 2, pp. 349-364
Closed Access | Times Cited: 99
UK guidelines for the management of soft tissue sarcomas
Andrew Hayes, Ioanna Nixon, D. Strauß, et al.
British Journal of Cancer (2024)
Open Access | Times Cited: 18
Pazopanib in advanced soft tissue sarcomas
Alex T. J. Lee, Robin L. Jones, Paul H. Huang
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 77
ALT Positivity in Human Cancers: Prevalence and Clinical Insights
Danny MacKenzie, Andrea Watters, Julie T. To, et al.
Cancers (2021) Vol. 13, Iss. 10, pp. 2384-2384
Open Access | Times Cited: 62
Brightline-1: phase II/III trial of the MDM2–p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS
Patrick Schöffski, Mehdi Lahmar, Anthony Lucarelli, et al.
Future Oncology (2023) Vol. 19, Iss. 9, pp. 621-629
Open Access | Times Cited: 26
An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies
M S Anju, k Chandramohan, Rexeena Bhargavan, et al.
Journal of Molecular Histology (2024) Vol. 55, Iss. 3, pp. 227-240
Closed Access | Times Cited: 8
Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression
Kaifeng Jin, Ya-Wei Ding, Jingtong Xu, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010964-e010964
Open Access | Times Cited: 1
GAS41 promotes ITGA4-mediated PI3K/Akt/mTOR signaling pathway and glioma tumorigenesis
Guanglei Shang, Wenju Zhang, Yanjie Jia, et al.
Biochemical Pharmacology (2025), pp. 116747-116747
Closed Access | Times Cited: 1
Dedifferentiated Liposarcoma: Systemic Therapy Options
Zhubin Gahvari, Amanda Parkes
Current Treatment Options in Oncology (2020) Vol. 21, Iss. 2
Closed Access | Times Cited: 65
Proteomic research in sarcomas – current status and future opportunities
Jessica Burns, Christopher P. Wilding, Robin L. Jones, et al.
Seminars in Cancer Biology (2019) Vol. 61, pp. 56-70
Open Access | Times Cited: 60
Biology and Management of Dedifferentiated Liposarcoma: State of the Art and Perspectives
Jun Nishio, Shizuhide Nakayama, Kazuki Nabeshima, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 15, pp. 3230-3230
Open Access | Times Cited: 51
The proteomic landscape of soft tissue sarcomas
Jessica Burns, Christopher P. Wilding, Lukáš Krásný, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 22
Chemotherapeutic drugs for soft tissue sarcomas: a review
Zhichao Tian, Weitao Yao
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 21
Pleomorphic Liposarcoma Unraveled: Investigating Histopathological and Immunohistochemical Markers for Tailored Diagnosis and Therapeutic Innovations
Ana-Maria Ciongariu, Dana Antonia Țăpoi, Adrian Dumitru, et al.
Medicina (2024) Vol. 60, Iss. 6, pp. 950-950
Open Access | Times Cited: 7
A first-in-human phase I study of a novel MDM2/p53 inhibitor alrizomadlin in advanced solid tumors
Xun Zhang, X. Wen, Ruiyun Peng, et al.
ESMO Open (2024) Vol. 9, Iss. 8, pp. 103636-103636
Open Access | Times Cited: 7
Diagnosis and Prognosis of Retroperitoneal Liposarcoma: A Single Asian Center Cohort of 57 Cases
Jianchun Xiao, Jianghao Liu, Minting Chen, et al.
Journal of Oncology (2021) Vol. 2021, pp. 1-10
Open Access | Times Cited: 37
A scoring system combining clinical, radiological, and histopathological examinations for differential diagnosis between lipoma and atypical lipomatous tumor/well-differentiated liposarcoma
Yohei Asano, Shinji Miwa, Norio Yamamoto, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 23
Myxoid Liposarcomas: Systemic Treatment Options
Elise F. Nassif, Emily Z. Keung, Prapassorn Thirasastr, et al.
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 4, pp. 274-291
Closed Access | Times Cited: 15
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action
Neeta Somaiah, William D. Tap
Cancer Treatment Reviews (2023) Vol. 122, pp. 102668-102668
Open Access | Times Cited: 15
Translocation-Related Sarcomas
Kenji Nakano, Shunji Takahashi
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 12, pp. 3784-3784
Open Access | Times Cited: 44
Comprehensive immune characterization and T‐cell receptor repertoire heterogeneity of retroperitoneal liposarcoma
Yan Liang, Zhen Wang, Can Cui, et al.
Cancer Science (2019) Vol. 110, Iss. 10, pp. 3038-3048
Open Access | Times Cited: 38
Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection
Ekaterina A. Lesovaya, Timur I. Fetisov, B. Yu. Bokhyan, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 271-271
Open Access | Times Cited: 4
Prediction of metabolites associated with somatic mutations in cancers by using genome-scale metabolic models and mutation data
GaRyoung Lee, Sang Mi Lee, Sungyoung Lee, et al.
Genome biology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top